Trial Profile
A Phase 1a/1b Study of LY3415244, a Bispecific Antibody in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs LY 3415244 (Primary)
- Indications Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 10 Mar 2021 Results assessing role of neutralizing antibody drug antibodies (ADAs) on safety and efficacy of LY3415244, published in the Clinical Cancer Research
- 13 Jan 2021 Results published in the Clinical Cancer Research
- 08 Nov 2019 Status changed from active, no longer recruiting to discontinued.